LONE TREE, Colo.–(BUSINESS WIRE)–Zynex, Inc. (OTCBB: ZYXI), a provider and developer of non-invasive medical
devices for electrotherapy and stroke rehabilitation, neurological diagnosis
and cardiac monitoring, announced that it has been ranked 127th on Deloittes
2011 Technology Fast 500 list for revenue growth between 2006 and 2010. The
same list categorizes companies into various industries and Zynex was ranked 9th
in growth among all medical equipment companies in the U.S. and Canada. The list also indicates
that Zynex is the fastest growing medical equipment company in the Rocky Mountain
region (for two years in a row), as well as 2nd fastest growing company in Colorado among all
technology companies. The Deloitte Technology Fast 500 list can be found at www.fast500.com.
Zynexs revenue grew 842% from the period of 2006 to 2010,
with revenue in 2010 of $24,085,000.
About The Deloitte Technology Fast 500™
Each year companies innovate, overcome obstacles and systematically defy the
odds. The Technology Fast 500 program recognizes these efforts in its annual
ranking of the 500 fastest-growing technology companies in the United States and Canada. The program is based
on percentage revenue growth from 2006 to 2010 and recognizes all areas of
technology and includes both public and private companies.
About Zynex
Zynex, Inc. (founded in 1996), operates under three primary business segments;
Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex
Medical engineers, manufactures, markets and sells its own design of
electrotherapy medical devices for standard digital electrotherapy, used for
pain relief, pain management and stroke and spinal cord injury rehabilitation.
Zynex Medicals product lines are fully developed, FDA-cleared, commercially
sold, and have been developed to uphold the Company’s mission of improving the
quality of life for patients suffering from impaired mobility due to stroke,
spinal cord injury, or debilitating and chronic pain. Zynex NeuroDiagnostics,
currently in the development stage, has been established to market EMG, EEG,
sleep pattern, auditory and nerve conductivity neurological diagnosis devices
through product development or acquisitions. Zynex Monitoring Solutions,
currently in the development stage, has been established to develop and market
medical devices for non-invasive cardiac monitoring. For additional information
please visit: http://www.ir-site.com/zynex/default.asp.
Safe
Harbor Statement
Certain statements in this release are “forward-looking” and as such
are subject to numerous risks and uncertainties. Actual results may vary
significantly from the results expressed or implied in such statements. Factors
that could cause actual results to materially differ from forward-looking
statements include, but are not limited to, the inability to agree on final
transaction terms with NeuroDyne, the need to obtain additional capital in
order to grow our business, our ability to engage additional sales
representatives, the success of such additional sales representatives, the need
to obtain FDA clearance and CE marking of new products, the acceptance of new
products as well as existing products by doctors and hospitals, larger
competitors with greater financial resources, the need to keep pace with
technological changes, our dependence on the reimbursement from insurance
companies for products sold or rented to our customers, acceptance of our
products by health insurance providers, our dependence on third party
manufacturers to produce our goods on time and to our specifications,
implementation of our sales strategy including a strong direct sales force, the
uncertain outcome of pending material litigation and other risks described in
our filings with the Securities and Exchange Commission including the “Risk
Factors” section of our Annual Report on Form 10-K for the year ended December
31, 2010.
